Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paula Rodriguez-Otero

Showing results (61-70 of 78) with videos related to

Pageof 8
Sort By:
Blood Cancer Discovery|March 11, 2026
Genetic evidence against clonotypic B-lymphocytes as reservoir of plasma-cell cancersCarmen González, Juan-Jose Garces, Hector Gracia, et al.
Blood|May 22, 2025
Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichmentMarta Lasa, Carmen Gonzalez, Laura Notarfranchi, et al.
Blood|December 17, 2025
Selective depletion of B-cell subsets underlies increased risk of infection in MM patients treated with anti-BCMA vs -GPRC5D bsAbsTomas Jelinek, David Žihala, Aintzane Zabaleta, et al.
Leukemia|June 2, 2020
Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myelomaJuan-José Garcés, Gabriel Bretones, Leire Burgos, et al.
The Lancet. Haematology|June 28, 2025
Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma NetworkNiels W C J van de Donk, Philippe Moreau, Jesús F San-Miguel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2024
Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd MaintenanceMaría-Victoria Mateos, Joaquin Martínez-López, Paula Rodriguez Otero, et al.
Science Advances|September 30, 2022
CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcomePaula Rodriguez-Marquez, Maria E Calleja-Cervantes, Guillermo Serrano, et al.
The Lancet. Oncology|May 2, 2024
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myelomaPaula Rodriguez-Otero, Saad Usmani, Adam D Cohen, et al.
Hemasphere|April 25, 2025
High-risk features of early relapse in newly-diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapyAndrea Manubens, Bruno Paiva, Norma C Gutiérrez, et al.
Hemasphere|November 27, 2025
Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma NetworkNiels W C J van de Donk, Philippe Moreau, Jesus F San-Miguel, et al.
Pageof 8

Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
Blood Cancer Discovery|March 11, 2026
Genetic evidence against clonotypic B-lymphocytes as reservoir of plasma-cell cancersCarmen González, Juan-Jose Garces, Hector Gracia, et al.
Blood|May 22, 2025
Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichmentMarta Lasa, Carmen Gonzalez, Laura Notarfranchi, et al.
Blood|December 17, 2025
Selective depletion of B-cell subsets underlies increased risk of infection in MM patients treated with anti-BCMA vs -GPRC5D bsAbsTomas Jelinek, David Žihala, Aintzane Zabaleta, et al.
Leukemia|June 2, 2020
Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myelomaJuan-José Garcés, Gabriel Bretones, Leire Burgos, et al.
The Lancet. Haematology|June 28, 2025
Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma NetworkNiels W C J van de Donk, Philippe Moreau, Jesús F San-Miguel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2024
Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd MaintenanceMaría-Victoria Mateos, Joaquin Martínez-López, Paula Rodriguez Otero, et al.
Science Advances|September 30, 2022
CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcomePaula Rodriguez-Marquez, Maria E Calleja-Cervantes, Guillermo Serrano, et al.
The Lancet. Oncology|May 2, 2024
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myelomaPaula Rodriguez-Otero, Saad Usmani, Adam D Cohen, et al.
Hemasphere|April 25, 2025
High-risk features of early relapse in newly-diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapyAndrea Manubens, Bruno Paiva, Norma C Gutiérrez, et al.
Hemasphere|November 27, 2025
Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma NetworkNiels W C J van de Donk, Philippe Moreau, Jesus F San-Miguel, et al.
Pageof 8